SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-18-030939
Filing Date
2018-12-14
Accepted
2018-12-14 16:16:11
Documents
40
Period of Report
2018-10-31

Document Format Files

Seq Description Document Type Size
1 Q2-19 FORM 10Q kalv-10q_20181031.htm 10-Q 1075890
2 EX-31.1 kalv-ex311_6.htm EX-31.1 21433
3 EX-31.2 kalv-ex312_7.htm EX-31.2 18690
4 EX-32.1 kalv-ex321_8.htm EX-32.1 8626
5 GRAPHIC gvk1tsp0je4d000001.jpg GRAPHIC 10903
  Complete submission text file 0001564590-18-030939.txt   2705635

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT kalv-20181031.xml EX-101.INS 319238
7 XBRL TAXONOMY EXTENSION SCHEMA kalv-20181031.xsd EX-101.SCH 25077
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE kalv-20181031_cal.xml EX-101.CAL 35863
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE kalv-20181031_def.xml EX-101.DEF 51519
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE kalv-20181031_lab.xml EX-101.LAB 189309
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kalv-20181031_pre.xml EX-101.PRE 133490
Mailing Address ONE KENDALL SQUARE BUILDING 200, STE. 2203 CAMBRIDGE MA 02139
Business Address ONE KENDALL SQUARE BUILDING 200, STE. 2203 CAMBRIDGE MA 02139 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

IRS No.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 10-Q | Act: 34 | File No.: 001-36830 | Film No.: 181235749
SIC: 2834 Pharmaceutical Preparations